Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?  

Short answer: yes. Although we have data from CREATE-X, data from GEICAM were negative. Data from FinXX and SYSUCC001, however, were positive. TNBC still carries a high risk of recurrence even with small-volume residual disease. Retrospective and prospective data suggest that chemotherapy is particu...